Clinics in Perinatology 2003: Vol 30 Index

21 Pages·2003·2.9 MB·English

CLINICS IN
PERINATOLOGY
Clin -erinatol 30 (2003) 875 894
Cumulative Index 2003
Volume 30
March ETHICS IN PERINATAL MEDICINE, pages | 7
June EVIDENCE-BASED MEDICINE, pages 189-438
September MATERNAL-FETAL SURGERY, pages 439-649
December PRETERM LABOR, pages 651 894
age numbers of article titles are in boldface type
\ Aminophylline, for preterm labor, 821
Abacavir, for HIV infection, in pregnancy, Amniocentesis
labor and delivery, 862 for anomaly detection
emotional support for, 115
Abortion
failure to inform about, 114
induced
premature membrane rupture in, amnio
fetal personhood and, 158
for anomalies, 113—114 patch technique for, 574 580
availability of, 117 serial, for twin twin transfusion
syndrome, 594-597
decision-making on,
113-114, 118 119 Amnionitis. See Chorioamnionitis
legality of, 71]
Amniotic fluid
methods for, 119 abnormal volumes of. See Oligohydram
viability definition and,
nios; Polyhydramnios
119-121
amniopatch technique involving, for
for genetic indications, 90 9] premature membrane rupture,
for nonmedical reasons, FIGO 574—580, 586—587
ethical guidelines for, 57
culture of, 683 684
for sex selection, 89 in gastroschisis, 559 564
selective. See Selective termination exchange or infusion of, 561 564
terminology recommendations for, 20
inflammatory effects of, 559 S61
Academ3i]c p3e2r93 f ormance, follow-up data in, Amoxicillin, for intrauterine infections,
688 — 689, 69]
Acardiac twin, in twin reversed arterial Ampicillin, for intrauterine infections, 687, 689
perfusion sequence, 602-603
Amprenavir, for HIV infection, in pregnancy
Access to care, in managed care, |7 2 ha labor and delivery, 863
Anastomoses, placental, in twin—twin
AIDS. See Human immunodeficiency
transfusion syndrome, 592—593
Virus infection
Anencephaly, viability questions in, 119-12]
American College of Surgeons, guidelines of,
for maternal-fetal surgery, 142 \neuploidy, nuchal translucency screening for,
95-102
American Society for Reproductive Medicine reliability of, 95 98
Ethics Committee, on gender selection, respect for autonomy in, 100
75 5
risks versus benefits of, 9&8 99
0095-5108/03/$ — see front matter « 2003 Elsevier Inc. All rights reserved
doi: 10.1016/S0095-5 108(03)00126-X
Cumulative Index / Clin Perinatol 30 (2003) 875-894
Anhydramnios Benchmarking techniques, 343-350
in fetal distal urinary obstruction, 507 abuses of, 347
511-512, 515 limitations of, 345
in gastroschisis, 553 patient protection in, 348
to improve quality of practice, 348
Anomalies, fetal. See Fetus, anomalies in
uses of, 344-346
Antenatal surgery. See Maternal -— fetal surgery
Beneficence
Antibiotics in fetal anomaly management, 122-123
for asymptomatic premature infants, in maternal —fetal surgery for spina
treatment decisions in. See bifida, 456—457
Treatment decisions in nuchal translucency screening, 98-99
for intrauterine infections, 687-691, Bentham, Jeremy, ethics theory of, 6
718-720
for preterm premature rupture of Beta-adrenergic agonists, for preterm labor,
membranes, 828 — 829 818—820
Aortic stenosis, treatment of, 544—54 Beta-sympathomimetic agents, for preterm
labor, 817-820
\pnea, neonatal, methylxanthines for,
treatment decisions in. See Betamethasone, antenatal, for fetal maturation,
829-833
Treatment decisions
Arachidonic acid, in prostaglandin synthesis, in Biopsy, kidney, in distal urinary tract
uterine activity, 807 obstruction, 513
Ascites, in distal urinary tract obstruction, 510 Bipolar coagulation, of umbilical cord, in
multifetal pregnancies, 611—616
Assisted reproduction technologies
multifetal pregnancy in. See Birthweight, in multifetal pregnancy, selective
Multifetal pregnancy reduction effects on, 106-107
preterm birth risk with, 659
Bladder
\tazanzvir, for HIV infection, in pregnancy, embryology of, 508
labor and delivery, 863 obstruction of. See Urinary tract
obstruction, distal
\tosiban, for preterm labor, 822, 849
Blastocyst, 29, 39
\trial septum, intact, treatment of, 545-546
Blastomeres, 29
\utonomy
in decision-making about fetal anomalies, Bleeding, vaginal, preterm birth in, 657
118-119
Blood transfusions, refusal of, in pregnancy,
in maternal — fetal surgery for spina 130—131. 135
bifida, 453—455
reproductive freedom component of, 114 Brain death, 36
respect for, in nuchal translucency
screening, 100 Braxton Hicks contractions, 809-810
Breastfeeding, avoidance of, in HIV
infection, 872 .
Bronchopulmonary sequestration
B diagnosis of, 482—483
Bacterial vaginosis, preterm birth in, 655-656, natural history of, 484
686-687, 690-691 size of, 481
surgical treatment of, 486-487
Balloon
for tracheal occlusion, in congenital
diaphragmatic hernia, 469—473
for valvuloplasty. See
Valvuloplasty, balloon
C -_—————
Bayley Scales of Infant Development, Calcium, in uterine activity, 806-807
follow-up data in, 228
Calcium channel blockers, for preterm labor,
Bedrest, for preterm labor, 813—814 820-821, 849-850
Cumulative Index / Clin Perinatol 30 (2003) 875-894
apitation, in managed care, 170 corticosteroids for, 830
diagnosis of, 679
arder, Angela, court-ordered cesarean section mechanisms of, 684
on, 129-134 organisms causing, 683-684
are, access to, in managed care, 172—173 origin of, 685
premature rupture of membranes
atheters in, 691
for thoracoamniotic shunting, 485—486 treatment of, 687-691
for vesicoamniotic shunting, 513—515 versus gestational age, 681 —682
ephallalo centesie s, i in hydrocecpehaplnuasl,u s, 533 Chorionic villi sampling
before multifetal pregnancy
erebral palsy, motor development in reduction, 632
227-228
before selective reduction, 108— 109
premature membrane rupture in,
ervicovaginal fibronectin. See
amniopatch technique fot
Fibronectin, fetal
574-580
ervix
Chromosomal abnormalities
incompetence of
in discordant twins, 603
preterm labor in, 808—809
ultrasound evaluation of, 749-752 in gastroschisis, $52
in multifetal pregnancies, 605-606,
length of, preterm birth risk and, 654
631—632
preparation of, for labor, 810
1 twin reversed arterial perfusion
ultrasound evaluation of, 735—755
sequence, 602
in preterm birth prediction,
738—749 selective termination for. See
Selective termination
cervical incompetence in,
749~—752 hronic lung disease, prevention of
in asymptomatic women, dexamethasone in, evidence-based
738-741. 744-747 decision-making in, 238—239
in multifetal pregnancy,
lewell, William, maternal -— fetal surgery
146—747
in singleton pregnancy, research by, 442—445
744-749
lindamycin, for intrauterine infections, 689
in symptomatic women,
742-743 ochrane neonatal systematic revie
landmarks for, 736 285-304, 335-33 6, 391
technique for, 736—738 results of, 28 299
versus clinical examination characteristics of included trials,
288—289
Cesarean delivery distribution across subject
for HIV infection, 865, 868 areas, 288
for nonmedical reasons, FIGO ethical growth of output, 287
guidelines for, 53—54 observations on review
managed care impact on methodologies, 299-300
refusal of reviewers’ conclusions, 291, 299
legal issues in, 129—133 size and precision of estimate of
survey on, 134-139 treatment effect, 290—291
size of reviews, 290
Chemical phenomenon, in gastroschisis, 553
therapies with extensive versus
Chiari malformation, with myelomeningocele, limited testing, 291]
523-526
survey methods in, 286—287
Chorioamnionitis Cognitive development, follow-up data in,
in maternal-— fetal surgery, for lung 228-230
lesions, 487
neonatal outcomes in, 685 Common sense, in ethics, 9
preterm birth in, 655—656 ‘ommunication, 17—25
asymptomatic, 681 alternative word choices for,
chronicity of, 682-682 discriminatory, 18—19
clinical features of, 680 impact on memory, 17—18
Cumulative Index / Clin Pe rinatol 30 (2003) 875-894
importance of, 17-18 in preterm premature rupture of
medical language for, 19 membranes, 828— 830
obstetric language for, 20 National Institutes of Health
of fetal anomaly test results, 115—117 recommendations on, 836—837
prenatal diagnosis language for, 20—24 single versus multiple courses of,
sexist, 18—19 833-835
Confidentiality, of genetic data, 87-88 Council of Europe, ethics code of, 51
Congenital anomalies. See Fetus, anomalies in. Counseling
Congenital cystic adenomatoid malformation, on fetal anomalies
of lung, 481-492 postviability, 122—124
animal studies of, 484-485 previability, 118-119
clinical features of, 481 on selective termination, in multifetal
diagnosis of, 482—483 pregnancies, 604-606
natural history of, 484 Cryoprecipitate, in amniopatch, for premature
pathology of, 482 membrane rupture, 574-580, 586—587
size of, 482
surgical treatment of, 485—488 Culture, of amniotic fluid, 683—684
types of, 482 Cystic adenomatoid malformation volume
Congenital diaphragmatic hernia, 465-479 ratio, 484
animal studies of, 467
Cystoscopy, for distal urinary tract obstruction,
delivery with, 473-474
515-516
incidence of, 465
mortality in, 465, 467, 475 Cytogenetic analysis, in multifetal
natural history of, 466—467 pregnancies, 605
prognosis for, 466—467
Cytokines
treatment of
postnatal, 474—475 in chorioamnionitis, 679, 684
prenatal, 467 —473 in gastroschisis, 557—558
ultrasonography in, 466—467 in preterm birth, 655—65
Congenital heart disease, 541-550 Cytomegalovirus infections, preterm birth
diagnosis of, 542—543 in, 694
etiology of, 543
in gastroschisis, 554-555
treatment of
anesthesia in, 547 D
aortic stenosis, 544
daVinci system, for maternal -— fetal
intact atrial septum,
surgery, 528
mitral stenosis, 545
rationale for, 543 —544 De Lia, Julian, maternal — fetal surgery research
right-sided defects, 546 by, 445-446
techniques for, 547-548
Death
onsequentialism, 6 fetal, in maternal infections, 692—694
maternal, pregnancy management
onstr5ic5t2i-ve5 53p henomenon, in gastroschisis, guidelines for, 53
Decision-making
ontractions, uterine. See Uterus, contractions
of; Home uterine activity monitoring. evidence-based. See Evidence-based
decision-making.
‘orpus luteum, ultrasonography of, 39 in genetic counseling, 84—86
in preimplantation diagnosis, of Down
orticosteroids, antenatal, for fetal maturation,
syndrome, 74—75
$27—842
on abortion
American College of Obstetricians and
for anomalies, 113—114, 118—119,
Gynecologists opinion on, 837
122-124
drug selection for, 830—833
for trisomy 13, 121-122
effects of, 827-828
for trisomy 18, 121-122
evidence-based decision-making in,
409-412 Declaration of Helsinki, 60—63
Cumulative Index / Clin Perinatol 30 (2003) 875-894
Delavirdine, for HIV infection, in pregnancy, Drainage
labor and delivery, 862 in thoracoamniotic shunting, 485—486
in vesicoamniotic shunting, 513—515
Delivery, managed care impact on, 175 of sacrococcygeal teratoma,
Denver shunt, in hydrocephalus, 534—535 497-498, 501
Dystocia, with large sacrococcygeal
Deontology, 6
teratoma, 494
Department of Health and Human Services,
maternal-fetal surgery research guidelines
of, 146-152
Economic issues
Dexamethasone in managed care, 169—171
antenatal, for fetal maturation, 829—833 in multifetal pregnancies, 624—6
to prevent chronic lung disease, in preterm birth, 666, 757—758
evidence-based decision-making in, home uterine activity monitoring
230-230 impact on, 783—784, 787
Diagnostic tests, 189-204 Education, in ethics, 1-15
benefit of, to patient, 201 —22 02 core generic course in, 11—13
posttest probability of disease and, 20] for perinatal medicine, 13
pretest probability of disease and, 201 impact of, 13-14
reproducibility of, 201 introduction to, 10-11
research literature on, 197—202 phases of, 10-13
case scenario in, 197, 202 principles of
search of, for best available study definitions of, |
197-198 medical ethics v
study appropriateness in, 199—200 ethics, 2
study validity in, 198-199 moral certainty,
screening, 196-197 reasoning, 3—5
sensitivity, specificity, and likelihood trust, 6-9
ratio in, 190— 191, 200 process of, 9-10
purpose of, 9-10
Diaphragmatic hernia. See Congenital
theories for, 6-8
diaphragmatic hernia
favirenz, for HIV infection, in pregnancy,
Diazoxide, for preterm labor, 822 labor and delivery, 863
Didanosine, for HIV infection, in pregnancy, lectrical properties, of myometrium
labor and delivery, 859-860, 862 667— 669
Diltiazem, for preterm labor, 849-850 lectromyography, uterine, 670—674
Disability mnbbdoolt zatioj n, Of f uummbbiilliiccaall vev essel]s , inn secleelcetcitivvee
prevention of, with preimplantation termination, in multifetal pregnancies,
genetic diagnosis, controversy over 606— 608
ms
mbryo(s)
threat of, maternal—fetal surgery for
as beginning ol human life, 32
spina bifida and, 459-460 definition of, 36
extracorporeal, moral status of, 70—71
Doppler studies, in congenital heart disease,
research on, ethical issues in, 36—37
542 —543, 545
transfer techniques for, preterm birth risk
Down syndrome in, 659
nuchal translucency screening for, ultrasonography of, 40—42
95-102 Embryo-chorionic circulation, ultrasonography
reliability of, 95—98
of, 40
respect for autonomy in, 100
risks versus benefits of, 98-99 Embryogenesis, 29—30
preimplantation diagnosis of, Emotional development, follow-up data in, 230
decision-making in, 74—75
prenatal detection of, failure to inform Emotional support, for fetal anomaly detection
about, 114 and management, 115
880 Cumulative Index / Clin Perinatol 30 (2003) 875-894
Emtricitabine, for HIV infection, in pregnancy, United Nations Educational,
labor and delivery, 862 Scientific, and Cultural
Organization, 50
Endometrium, microorganism colonization of, World Health Organization, 50—51
preterm birth in, 656 communication and, 17—25
definition of, 45
Endoscopy, for premature ruptured membrane
education in, 1-15
assessment, 580—584
evidence-based. See
Enfuvirtide, for HIV infection, in pregnancy, Evidence-based ethics.
labor and delivery, 863 of beginning of human life, 27—44
of fetal anomaly screening, 113-126
EnI zymtehi-e-l inkeCdC immunoNOsSoCr benc t aassssc ay of genetic counseling, 81-93
for fetal fibronectin, 704 of managed care, 167-180
for salivary estriol, 721 of maternal — fetal surgery
for congenital heart defects, 543
Equipoise criterion, in maternal-fetal surgery for multifetal pregnancy reduction,
for myelomeningocele, 162-163
623-624
for myelomeningocele, 155-165
Erythromycin, for intrauterine infections,
for spina bifida, 449-464
687—691 autonomy in, 453—455
Estriol, salivary, as preterm birth predictor, beneficence in, 456—457
at ss clinical emphasis in, 451
20 2
background of, 720—723 controversy over, 449—450
elective interventions in,
confounding factors in, 72! —7423
in asymptomatic women, 723—724 458 — 459
in multifetal pregnancy, 726 moral ideas on, 451]
in symptomatic women, 724-726 457-458
intervention studies of, 726—727 potential abuse of, 461 —462
predisposition to treatment in,
Ethanol, for preterm labor, 815—816 460-461
religious context of, 452—453
Ethics risk considerations in,
codes of, 45-65 457—458
Council of Europe, 51
threat of disability in,
FIGO (International Federation of 459-460
Gynecology and Obstetrics) uncertainty in, 45;
Committee, for Study of vulnerability in, 454
Ethical Aspects of Human in research programs, 141
Reproduction, 51 —58 of nuchal translucency screening,
for cesarean delivery for
95-102
nonmedical reasons, 53 —54 of preimplantation diagnosis. See
for induced abortion for Preimplantation genetic diagnosis
nonmedical reasons, 57—59 of refusal of treatment, 127-140
for management of newborns at
of selective reduction, 103-111
threshold of viability, 54—56
for management of severely Ethnic factors, in preterm birth, 651, 656
malformed newborns, 56—57
Eugenics, 86—87
for pregnancy management in
sudden maternal death, 53 Evidence-based decision-making. See also
for prenatal diagnosis, 52—53 Therapeutic evidence;
for research on human subjects, Treatment decisions.
59-63 follow-up data in, 217-250
from hospital ethics committees, choice of outcomes to study,
46—48 ,) ] g 224
from international ethics examples of, 238—240
committees, 49—58 group difference in, 233, 237—238
from national ethics committees, health-related quality of life, 224
48—49 neonatal outcome as predictor
new technology impact on, 45-46 of, 225
patient-physician relationship neurodevelopment after age 2,
and, 46 999 , 39
Cumulative Index / Clin Perinatol 30 (2003) 875-894 881
academic performance, curriculum evaluation in, 430—431
y2 5 329 obtain information with maximum
cognitive development, efficiency, 426—428
229-230 recognize need for information and
motor development, 229 put in form of answerable
social and emotional question, 425-426
deveiopment, 230 strategies for, 421—423
neurodevelopment at | to 2 years of to faculty, 425
age, 226—228 to medical students, 423-424
cognitive development, 228
hearing assessment, 2) 26 97 to residents and fellows, 424—425
motor development, 227—228 Evidence-based ethics, for extremely
vision assessment, 227 premature infants, 363—387
no group difference in, 232-233 based on credible evidence, 366
in neonatal intensive care unit. Sec boundaries for care categories in,
Neonatal intensive care unit 379-38] :
promoting uptake and use of, 389-402, chance of survival and, 366
403-417 cost-effectiveness in, 373—375
analysis of uptake process, definition of, 364
404-405 effects on families in, 377
clinician awareness of ry p T oven futility of care, 364—366
therapies, 391 —39 405-406 need for improved studies of, 381
clinician belief in evidence, 406 outcome measurements in, 368-369
clinician commitment to patient factors in, 369-373
change, 407 preventing quandaries in, 382—383
definition of effectiveness roles of parents and physicians in,
389-39] 23770 8—(3#27 9
dissemination of new information,
treatment withdrawal in, 377
393-397 types of therapeutic studies in, 367
clinician factors in, 396—397
use of resources and distress to infants
comparison of methods for,
394-396 versus benefits, 375—376
evaluation of new therapies Ex utero intrapartum treatment (EXIT), 1
390-39] congenital diaphragmatic hernia,
evidence to support particular 473-474
strategy, 405
examples of, 409-415 Experimental therapy, in managed care, 173
antenatal steroids for fetal Extracorporeal membrane oxygenation, for
maturation, 409—412 congenital diaphragmatic hernia,
National Partnership to Help 474-475
Pregnant Smokers Quit
412-414
smoking cessation in routine
care, 414-415
implementation, monitoring, and
maintenance of change, 408 Fee for service, negotiated, in managed care,
inappropriate underuse of proven 1ri7O e— hs7 1
therapies, 397-399 Feminist ethics, 7
peer endorsement of evidence,
406-407 Ferritin, in gastroschisis, 558
perception of gap between practice
Fertilization
and evidence, 407
in vitro, multifetal pregnancy in, selective
support for change by practice
reduction in, 103—111
setting, 407—408
life beginning at
synergistic effects of interventions, ‘
arguments against, 32—33
408 —409
arguments for, 31 —32
teaching of, 419—433
apply information to problem and Fetoscope
evaluate outcome, 429-430 iatrogenic membrane rupture from, am-
critically appraise evidence, niopatch technique for, 574—580
428—429 invention of, 440-441
882 Cumulative Index / Clin Perinatol 30 (2003) 875-894
Fetus Financial considerations, in genetic
anomalies in, 113-126 counseling, 92
communication about Fluid therapy, for preterm labor, 814
See Communication
lethal, hospice care in, 123 Formulary, limited, in managed care, 173
management of
aggressive, 117, 122—124
balancing approach to,
ii7, 123 Gamete intra-fallopian transfer, preterm birth
nonaggressive, 117, 122~—12 4 risk in, 659
options for, 117 Gastroesophageal reflux, treatment decisions
postviability counseling and in. See Treatment decisions
decision-making on,
122-124 Gastroschisis, 551—572
amnioexchange and amnioinfusion
preimplantation detection of.
procedures for, 561—564
See Preimplantation amniotic fluid impact on, 559-562
genetic diagnosis animal models of, 557—559
previability counseling and consequence S ea 53
decision-making on, 118— 119 delivery in, 55¢
screening and detection of diagnosis of, 55
emotional support in, 115
ethical basis of, 113-114 genetic factors 1n,
giving bad news after, historical review of, 5
115-117 incidence of, 551]
selective reduction for, 108— 109 inflammation in,
monitoring of,
viability definition and, 119~— 122
outcome of, 55:
fibronectin related to. Sec postnatal care in, 554
Fibronectin, fetal prognosis for, $55—55
genetic counseling related to. See Genetic surgical treatment of, 554
counseling.
maturation of, antenatal steroid therapy Gender
in. See Corticosteroids, antenatal, medical language insensitive to, 19
prebirth selection for, 75—77, 89
for fetal maturation
sexist language and, 18 — 19
personhood of, 31, 156-160, 449-452
research on, ethics guidelines for, 62—63 Gene therapy, preimplantation genetic
surgery on. See Maternal -—fetal surgery diagnosis and, 92
ultrasonography of, 3D and 4D, 41 —42 Genetic counseling, 81—93
viability of. See Viability, of fetus counselor responsibilities in, 84—86
or newborn. decision rights in, 84—86
directive, 82
Fibrin formation, in amniopatch technique, 578
discrimination resulting from, 88 —89
ib.in glue, for premature rupture of history of, 81—82
membranes, 585—586 illness versus health considerations in,
89-90
Fibronectin, fetal means of, 82—84
as preterm birth predictor, 702 nondirective, 82, 84—86
assays for, 704—705 on financial costs, 92
confounding factors in, 705 on monogenic diseases, 86—87
historical background of, 702—705 on pregnancy termination, 90—91
in asymptomatic women, 706—709 on preimplantation diagnosis, 92
in multifetal gestations, 714—717 on presymptomatic diagnostics,
in symptomatic women, 710—714 confidentiality of data and, 87—88
intervention studies of, 17-720 on sex selection and determination, 89
in normal pregnancies, 702-704 religious considerations in, 91 —92
stigmatization resulting from, 88— 89
FIGO (International Federation of Gynecology
and Obstetrics) Committee, for Study of Gestational age
Ethical Aspects of Human Reproduction, at delivery, tocolysis effects on, 852
51-58 versus intrauterine infections, 681 —682
Cumulative Index / Clin -erinatol 30 (2003) 875-894
follow-up care in, 871
Harrison, Michael, maternal — fetal surgery eneral laboratory testing in, 859-860
IIV testing in, 858—859
research by, 441-442
neonatal care in, 871—872
Health, versus illness, genetic counseling obstetric procedures in, 868—869
89—90 postpartum care in, 871
Health maintenance organizations. Se¢ viral transmission prevention in,
860-868
Managed care
Hearing assessment, follow-up data in, Hydrocephalus, 443 —445, 531-539
196 227 anomalies associated with, 531 —53
classification of, 531
Heart disease, congenital. See Congenital
heart disease etiology
morbidity and mortality in,
Hernia, diaphragmatic. See Congenital 534—535
diaphragmatic hernia : h <9
myelomeningocele with, 52
Highly active antiretroviral therapy, for HI\ prevalence of, 531
infection, in pregnancy, labor and treatment of, 533—538
deliv ery 861 Hydronephrosis, in distal urinary tract
HIV infection. See Human immunodeficiency obstruction, 510
virus infection
Hydrops
Home uterine activity monitoring, 757—804 in lung lesions, 481—486
after tocolysis 787-791 in sacrococcygeal teratoma, 495 SUS
clinical trials overview of, 759
Hydroureters, in distal urinary tract
comprehensive system versus
obstruction, 510
self-palpation, 767—768
controversy over, 759-760 7-a-Hydroxyprogesterone, for preterm
devices for, 765—766 labor, @98272
during maintenance tocolytic therapy,
793—797 Hyperglycemia, from ritodrine, 819-820
economic impact of, 783—784, 78 Hypnotics, for preterm labor, 821 —822
false versus true, 766
frequency of, 764—765 Hypoplastic left heart syndrome
in multifetal pregnancy, 765, 781 —782 in aortic stenosis, 544—545
in secondary prevention clinical trials, in intact atrial septum, 545—546
768787 in mitral stenosis, 545
in socioeconomically disadvantaged Hypoplastic right heart syndrome, 543, 546
group, 783—784
Hypotension, in prem1a ture infants, inotropes
In tertiary prey ention clinical trials,
87—791 for, treatment decisions in. See
indications for, 75 59 Treatment decisions
miscellaneous studies on, 79]
preterm contractions, 764—765
preterm labor symptoms and, 766—767
protocol for, 761~— 764
recording strips produced in, 76] | Illness, versus health, genetic counseling and,
89-90
Hospice care, in lethal fetal anomalies,
123-124 Implantation, as beginning of human life, 33
Hospital ethics committees, 46—48 In vitro fertilization
multifetal pregnancy in, selective
Human Genome Project, genetic counseling
reduction in, 103-111
and, 86~—87
preterm birth risk in, 659
Human immunodeficiency virus infection,
Incompetence, cervical, ultrasound evaluation
preterm labor in, 857—876
of, 749-752
antenatal care in, 871]
clinical situations in, 869—8 0 Indinavir, for HIV infection, in pregnancy,
delivery mode in, 865 labor and delivery, 863
884 Cumulative Index / Clin Perinatol 30 (2003) 875-894
ndomethacin International Fetal Medicine and Surgery
for preterm labor, 816—817, 847, 849 Society, 444
prophylactic, in low birth weight infants,
International Fetoscopy Group, 440-441
evidence-based decision-making in,
239-240 Intestine
Infections exteriorization of, in gastroschisis, 5
pathology of, in gastroschisis, 553—554
neonatal effects of, 687
preterm birth in, 655—656, Intrauterine growth retardation
677-700, 809 after multifetal pregnancy reduction, 631
ascent of, 686 in gastroschisis, 554, 563
asymptomatic, 68|
bacterial vaginosis, 686-687 Intrauterine pressure catheters, for preterm
chronicity of, 682-683 labor detection, 667
diagnosis of, 679—680 Isoxuprine, for preterm labor, 818
fetal death in, 694
fetal fibronectin in, 704, 717—720
historical review ot, 677-679
markers of, 680
mechanisms of, 684 Justice principle, preimplantation genetic
organisms causing, 683 — 684 diagnosis and, 69
origin of, 685
premature rupture of membranes
in, 691
sexually transmitted, 691, 693-694 K -
Kant, Immanuel, ethics theory of, 6
treatment of, 687-691
types of. 680—681 Karyotyping, for genetic diagnosis in selective
versus gestational age, 681 — 682 reduction, 108-109
viral, 694
Keratinocyte growth factor, in congenital cystic
Infertility, treatments for adenomatoid malformation, 482
multifetal pregnancy in, 103
religious teachings on, 34 Kidney
biopsy of, in distal urinary tract
Inflammation, in gastroschisis, 557 obstruction, 513
562 —564 damage of, in urethral obstruction,
Informed choice, in maternal -— fetal surgery for 507-510
spina bifida, 460—461
Informed consent
for nuchal translucency screening, 100
for preimplantation genetic diagnosis, 69 Labor and delivery. See also Cesarean delivery
diagnosis of
Inotropes, for hypotension, in premature
clinical, 666-667
infants, treatment decisions in. See
electromyography in, 670-674
Treatment decisions
in congenital diaphragmatic hernia,
Intensive care unit, neonatal. See under 473-474
Neonatal intensive care unit in gastroschisis, 555
in HIV infection, 865, 868
Interleukin(s), in gastroschisis, 557—558, in hydrocephalus, : 533-534
562-563 in large sacrococcygeal teratoma, 494
International ethics committees premature. See Premature labor
codes of, 49—58 and delivery.
Council of Europe, 5 preparatory stage of, 669-670
United Nations Educational, Scientific,
Lamivudine, for HIV infection, in pregnancy,
and Cultural Organization, 50
labor and delivery, 862, 864
World Health Organization, 50-51
Language. See Communication
International Federation of Gynecology and
Obstetrics (FIGO) Committee, for Study Laser therapy
of Ethical Aspects of Human for premature rupture of membranes,
Reproduction, 51 —58 584-586